ADRB1
ENSG00000043591
Target class
GPCR
Chromosome
10
Approved drugs
44
Clinical candidates (approved and in development)
49
- Approved drugs
- 44
- Clinical candidates (approved and in development)
- 49
- Chemical probe available
- Yes
- Target name
- ADRB1
- Gene name
- Adrenoceptor beta 1
- Gene symbol
- ADRB1
- Previous gene symbols
- ADRB1R
- Protein name
- Beta-1 adrenergic receptor (Beta-1 adrenoreceptor) (Beta-1 adrenoceptor)
- Gene biotype
- Protein coding
- Gene family
- Adrenoceptors
- Target class
- GPCR
- Target type
- Human gene
- Tissues expressed in
- 28
- Highest tissue expression
- 24.29
- Tissue specificity (Gini)
- 0.659
- Tissue specificity (tau)
- 0.885
- KEGG gene identifiers
- hsa:153
- Protein interaction confidence
- 0.866037
- Protein interaction partners
- 27
- R-HSA-390696
- R-HSA-418555
- End position
- 114046904
- Start position
- 114043866
- Chromosome
- 10
- Strand
- Forward
- Cell membrane
- Multi-pass membrane protein . Note=Colocalizes with RAPGEF2 at the plasma membrane (By similarity). Localized at the plasma membrane (By similarity). Found in the Golgi upon GOPC overexpression (PubMed:15358775). Localized to early endosomes during endocytic trafficking (PubMed:21540189). .
- PubMed 33093660
- PubMed 15358775
- PubMed 21540189
- Tissue specificity (tau)
- 0.885037
- Expression inequality (Gini)
- 0.659271
Expression in transcripts per million
- Lung
- 24.29
- Heart - Atrial Appendage
- 14.6
- Heart - Left Ventricle
- 14.09
- Brain - Nucleus accumbens (basal ganglia)
- 12.9
- Brain - Cortex
- 12.03
Expression in transcripts per million
- Lung24.29
- Heart - Atrial Appendage14.6
- Heart - Left Ventricle14.09
- Brain - Nucleus accumbens (basal ganglia)12.9
- Brain - Cortex12.03
- Brain - Frontal Cortex (BA9)11.32
- Brain - Caudate (basal ganglia)6.94
- Brain - Anterior cingulate cortex (BA24)6.88
- Brain - Putamen (basal ganglia)6.07
- Prostate5.63
- Adipose - Visceral (Omentum)5.25
- Esophagus - Muscularis4.74
- Brain - Amygdala3.86
- Colon - Sigmoid3.59
- Esophagus - Gastroesophageal Junction3.41
- Small Intestine - Terminal Ileum2.97
- Brain - Hippocampus2.95
- Brain - Substantia nigra2.72
- Spleen2.45
- Artery - Coronary2.32
- Brain - Hypothalamus2.22
- Breast - Mammary Tissue2.18
- Adipose - Subcutaneous2.08
- Colon - Transverse1.97
- Brain - Cerebellum1.51
And 29 more, listed on the interactive page.
- GO:0001996
- GO:0007189
- GO:0045187
- GO:0071880
- GO:0005769
- GO:0005886
- GO:0004939
- GO:0004940
- GO:0005515
- GO:0030165
- GO:0031694
- GO:0046982
cardiac hypertrophy
Effects
- Activation/Increase/Upregulation: chronic
Studies
- preclinical: cardiac hypertrophy
Biological samples
- cardiovascular
PubMed 28216264decreased heart rate
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: decreased heart rate
Biological samples
- cardiovascular
PubMed 28216264increased heart rate
Effects
- Activation/Increase/Upregulation: general
Studies
- clinical: increased heart rate
Biological samples
- cardiovascular system
Evidence sourceincreased heart rate
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: increased heart rate
Biological samples
- cardiovascular
PubMed 28216264relaxation of blood vessels
Effects
- Activation/Increase/Upregulation: general
Studies
- clinical: relaxation of blood vessels
Biological samples
- cardiovascular system
Evidence sourcecardiovascular performance
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- clinical: cardiovascular performance
Biological samples
- cardiovascular system
Evidence sourcebradycardia
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- clinical: bradycardia
Biological samples
- cardiovascular system
Evidence sourceventricular fibrillation
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: ventricular fibrillation
Biological samples
- cardiovascular
PubMed 28216264bronchospasm
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: bronchospasm
Biological samples
- cardiovascular
PubMed 28216264cardiac muscle stimulation
Effects
- Activation/Increase/Upregulation: general
Studies
- clinical: cardiac muscle stimulation
Biological samples
- cardiovascular system
Evidence sourcemyocardial fibrosis
Effects
- Activation/Increase/Upregulation: chronic
Studies
- preclinical: myocardial fibrosis
Biological samples
- cardiovascular
PubMed 28216264heart failure
Effects
- Activation/Increase/Upregulation: chronic
Studies
- preclinical: heart failure
Biological samples
- cardiovascular
PubMed 28216264increased cardiac contractility
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: increased cardiac contractility
Biological samples
- cardiovascular
PubMed 28216264increased force of contraction
Effects
- Activation/Increase/Upregulation: general
Studies
- clinical: increased force of contraction
Biological samples
- cardiovascular system
Evidence sourcedecreased blood pressure
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: decreased blood pressure
Biological samples
- cardiovascular
PubMed 28216264
electrolyte disturbances
Effects
- Activation/Increase/Upregulation: general
Studies
- preclinical: electrolyte disturbances
- cardiovascular system
- gastrointestinal
PubMed 23197038receptor binding
Studies
- biochemical: NVS_GPCR_hAdrb1, is one of one assay component(s) measured or calculated from the NVS_GPCR_hAdrb1 assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.
Biological samples
- cell-free
Evidence sourceincreased cardiac contractility
Effects
- Activation/Increase/Upregulation: general
Studies
- preclinical: increased cardiac contractility
- cardiovascular system
- gastrointestinal
PubMed 23197038decreased cardiac output
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- preclinical: decreased cardiac output
- cardiovascular system
- gastrointestinal
PubMed 23197038increased renin release
Effects
- Activation/Increase/Upregulation: general
Studies
- preclinical: increased renin release
- cardiovascular system
- gastrointestinal
PubMed 23197038increased heart rate
Effects
- Activation/Increase/Upregulation: general
Studies
- preclinical: increased heart rate
- cardiovascular system
- gastrointestinal
PubMed 23197038decreased heart rate
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- preclinical: decreased heart rate
- cardiovascular system
- gastrointestinal
PubMed 23197038lipolysis
Effects
- Activation/Increase/Upregulation: general
Studies
- preclinical: lipolysis
- cardiovascular system
- gastrointestinal
PubMed 23197038relaxation of colon and oesophagus
Effects
- Activation/Increase/Upregulation: general
Studies
- preclinical: relaxation of colon and oesophagus
- cardiovascular system
- gastrointestinal
PubMed 23197038decreased blood pressure
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- preclinical: decreased blood pressure
- cardiovascular system
- gastrointestinal
PubMed 23197038
Related records
Trials (2,115)
- : Vascular Function in Health and Disease
- ''Efficacy of Propranolol in the Treatment of Infantile Hemangioma"
- "Pecos" B-adrenergic and PPAR-G Stimulation Upregulates Lipid Metabolism in Human Subcutaneous Fat
- "The Effect Of Subcutaneous Epinephrine Dosage On Blood Loss In Surgical Incision"
- "The Efficacy of Exparel Versus a Multidrug Cocktail in Soft Tissue Tumors"
- "The Evaluation of Stimulant Withdrawal"
- 10 Vs.15 mcg Norepinephrine Bolus in Severe Maternal Hypotension During Cesarean Delivery
- ¹³C-Methacetin Breath Test (MBT) Methodology Study
- 24 Hour Ambulatory Cardiac Oxygen Consumption
- 24-hour Control of Intraocular Pressure (IOP) in Ocular Hypertension
- 24-hour Efficacy and Ocular Surface With Talfuprost and Triple Combined Therapy
- 24-hour Efficacy and Tolerability of the Tafluprost-timolol Fixed Association Without Preservatives in Glaucomatous or Ocular Hypertensive Patients Already Treated With Latanoprost Preserved With BAK. A Prospective, Open Study of 3 Months Duration.
- 24-Hour Intraocular Pressure (IOP) And Blood Pressure Control In Glaucoma And Ocular Hypertension Patients
- 24-hour Intraocular Pressure (IOP) Control With the Bimatoprost/Timolol Fixed Combination
- 24-Hour Intraocular Pressure (IOP) Control With Travoprost/Timolol Fixed Combination
- 24-Hour Intraocular Pressure Control With Bimatoprost/Timolol Versus Latanoprost as First Choice
- 24-hour Intraocular Pressure Control With Travoprost/Timolol Fixed Combination Versus Travoprost
- 24-Hour Intraocular Pressure With Brinzolamide/Timolol Versus Brimonidine/Timolol
- 24-hour Study of Dorzolamide/Timolol and Latanoprost/Timolol Fixed Combinations
- 24-hr Intraocular Pressure Control With Dorzolamide/Timolol vs the Brimonidine/Timolol Fixed Combination
Drugs (74)
- Acebutolol Beta-1 adrenergic receptor antagonist
- Acebutolol hydrochloride Beta-1 adrenergic receptor antagonist
- Atenolol Beta-1 adrenergic receptor antagonist
- Betaxolol Beta-1 adrenergic receptor antagonist
- Betaxolol hydrochloride Beta-1 adrenergic receptor antagonist
- Bisoprolol Beta-1 adrenergic receptor antagonist
- Bisoprolol fumarate Beta-1 adrenergic receptor antagonist
- Bucindolol Beta-1 adrenergic receptor antagonist
- Bucindolol hydrochloride Beta-1 adrenergic receptor antagonist
- Carteolol Adrenergic receptor beta antagonist
- Carteolol hydrochloride Adrenergic receptor beta antagonist
- Carvedilol Adrenergic receptor beta antagonist
- Carvedilol phosphate Adrenergic receptor beta antagonist
- Celiprolol Beta-1 adrenergic receptor antagonist
- Dilevalol Adrenergic receptor beta antagonist
- Dilevalol hydrochloride Adrenergic receptor beta antagonist
- Dipivefrin Adrenergic receptor agonist
- Dipivefrin hydrochloride Adrenergic receptor agonist
- Dobutamine Beta-1 adrenergic receptor agonist
- Dobutamine hydrochloride Beta-1 adrenergic receptor agonist